ICU Medical Inc
ICUI
ISIN null / Valor 940704
ICU Medical Inc
UMushroom community rating:
About company
ICU Medical Inc is a global market leader in the healthcare industry, offering a comprehensive range of clinically-essential IV therapy and critical care products for various healthcare settings including hospitals, alternate sites, and home care. The company's acquisition of Hospira Infusion Systems in 2017 and Smiths Medical in 2022 has further solidified its position in the market, allowing it to provide high-value medical solutions to meet the needs of healthcare professionals and patients worldwide.
Summarized from source with an LLMView SourceSector: HealthcareLatest Results (03.10.2025):
ICU Medical Inc announced its fourth quarter 2023 financial results, demonstrating modest revenue growth in key product lines while the company continues to navigate operational challenges, resulting in an increased net loss compared to the previous year.
Total Revenue Growth
In the fourth quarter of 2023, ICU Medical Inc reported total revenues of $587.9 million, up from $578.0 million in the same period last year, marking a 1.7% increase.
Product Line Performance
The Consumables segment saw a revenue increase of $11.8 million year-over-year, while Infusion Systems experienced a slight decline of $3.9 million. Vital Care revenues grew by $1.9 million, partially offset by a decrease in Pfizer contract manufacturing revenue.
Net Loss Increase
The company reported a net loss of $17.1 million for Q4 2023, compared to a net loss of $15.5 million in Q4 2022, reflecting ongoing investment and operational expenses.
Strengthened Cash Position
As of the end of Q4 2023, ICU Medical Inc's cash and cash equivalents increased to $254.2 million from $208.8 million in Q4 2022, enhancing the company's liquidity position.
Summarized from source with an LLMView SourceKey figures
Performance
Volatility
3309 M
Market cap (USD)
182,697
Daily traded volume (Shares)
154.78 / 151.22
1 day high/low (USD)
52 weeks high/low (USD)
Dividend ex-date
Dividend (USD)
Dividend yield (p.a.)
Est dividend (USD)
Est dividend yield
P/E ratio
Est P/E ratio
EPS (USD)
Est EPS (USD)
Ratings & reviews
EQUITIES OF THE SAME SECTOR
